Mikel Gorostidi1, Blanca Gil-Ibañez2, Sonsoles Alonso3, Antonio Gil-Moreno4,5, Alicia Hernandez6, Aureli Torné7, Ignacio Zapardiel6. 1. Gynecologic Oncology Unit, Donostia University Hospital, San Sebastián, Spain. 2. Gynecologic Oncology Unit, Hospital Clinic, Barcelona, Spain. BLGIL@clinic.cat. 3. Gynecologic Oncology Unit, MD Anderson Cancer Center International, Madrid, Spain. 4. Gynecologic Oncology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 5. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain. 6. Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain. 7. Gynecologic Oncology Unit, Hospital Clinic, Barcelona, Spain.
Abstract
PURPOSE: To analyze the current management and use of fertility preservation (FP) treatments among different gynecologic oncology centers in Spain METHODS: From March to April 2019, a transversal study was conducted using a national online survey to consultants registered in the section of Gynecologic Oncology of the Spanish Society of Obstetrics and Gynecology. The survey contained 30 questions that assessed the perceptions and attitudes towards fertility-sparing strategies as well as its management in each participating center. RESULTS: A total of 51 responders from 12 out of 17 geographical regions of Spain answered the survey. According to 35 responders (68.63%), the age limit for offering FP was 40 years. In most of the centers, an ovarian reserve study is carried out prior to a FP procedure (34 responders, 66.67%). In cervical cancer size, limit for offering trachelectomy is 2 cm (40 responders, 78.43%), with LVSI as an exclusion factor for 26 (51%). Twenty-four (48.98%) responders reported that FP only in ovarian cancer stages IA, 12 (24.49%) also in stages IB, and an additional 13 (26.53%) up to stages IC. Most responders perform FP only in the absence of myometrial infiltration (30, 58.82%) in patients with g1-g2 endometrial cancer. CONCLUSIONS: The performance of professionals at the national level is uneven, demonstrating the need for referral centers to ensure optimal management. International guidelines should be more widely extended throughout Spain to homogenize the treatment of young oncology patients who wish to have children.
PURPOSE: To analyze the current management and use of fertility preservation (FP) treatments among different gynecologic oncology centers in Spain METHODS: From March to April 2019, a transversal study was conducted using a national online survey to consultants registered in the section of Gynecologic Oncology of the Spanish Society of Obstetrics and Gynecology. The survey contained 30 questions that assessed the perceptions and attitudes towards fertility-sparing strategies as well as its management in each participating center. RESULTS: A total of 51 responders from 12 out of 17 geographical regions of Spain answered the survey. According to 35 responders (68.63%), the age limit for offering FP was 40 years. In most of the centers, an ovarian reserve study is carried out prior to a FP procedure (34 responders, 66.67%). In cervical cancer size, limit for offering trachelectomy is 2 cm (40 responders, 78.43%), with LVSI as an exclusion factor for 26 (51%). Twenty-four (48.98%) responders reported that FP only in ovarian cancer stages IA, 12 (24.49%) also in stages IB, and an additional 13 (26.53%) up to stages IC. Most responders perform FP only in the absence of myometrial infiltration (30, 58.82%) in patients with g1-g2 endometrial cancer. CONCLUSIONS: The performance of professionals at the national level is uneven, demonstrating the need for referral centers to ensure optimal management. International guidelines should be more widely extended throughout Spain to homogenize the treatment of young oncology patients who wish to have children.
Entities:
Keywords:
Conservative treatment endometrial cancer; Early cervical cancer; Fertility preservation treatments; Gynecological cancer
Authors: Helena Robova; Michael J Halaska; Marek Pluta; Petr Skapa; Jan Matecha; Jiri Lisy; Lukas Rob Journal: Gynecol Oncol Date: 2014-08-23 Impact factor: 5.482
Authors: Andrea N Simpson; Tomer Feigenberg; Blaise A Clarke; Lilian T Gien; Nadia Ismiil; Stephane Laframboise; Christine Massey; Sarah E Ferguson Journal: Gynecol Oncol Date: 2014-02-19 Impact factor: 5.482
Authors: Sonika Agarwal; Kathleen M Schmeler; Pedro T Ramirez; Charlotte C Sun; Alpa Nick; Ricardo Dos Reis; Jubilee Brown; Michael Frumovitz Journal: Int J Gynecol Cancer Date: 2011-01 Impact factor: 3.437
Authors: Petra L M Zusterzeel; Fraukje J M Pol; Maaike van Ham; Ronald P Zweemer; Ruud L M Bekkers; Leon F A G Massuger; René H M Verheijen Journal: Int J Gynecol Cancer Date: 2016-09 Impact factor: 3.437
Authors: David Cibula; Richard Pötter; François Planchamp; Elisabeth Avall-Lundqvist; Daniela Fischerova; Christine Haie Meder; Christhardt Köhler; Fabio Landoni; Sigurd Lax; Jacob Christian Lindegaard; Umesh Mahantshetty; Patrice Mathevet; W Glenn McCluggage; Mary McCormack; Raj Naik; Remi Nout; Sandro Pignata; Jordi Ponce; Denis Querleu; Francesco Raspagliesi; Alexandros Rodolakis; Karl Tamussino; Pauline Wimberger; Maria Rosaria Raspollini Journal: Int J Gynecol Cancer Date: 2018-05 Impact factor: 3.437
Authors: Pedro T Ramirez; Michael Frumovitz; Rene Pareja; Aldo Lopez; Marcelo Vieira; Reitan Ribeiro; Alessandro Buda; Xiaojian Yan; Yao Shuzhong; Naven Chetty; David Isla; Mariano Tamura; Tao Zhu; Kristy P Robledo; Val Gebski; Rebecca Asher; Vanessa Behan; James L Nicklin; Robert L Coleman; Andreas Obermair Journal: N Engl J Med Date: 2018-10-31 Impact factor: 91.245
Authors: Antoni Llueca; Maria Victoria Ibañez; Aureli Torne; Antonio Gil-Moreno; Angel Martin-Jimenez; Berta Diaz-Feijoo; Anna Serra; Maria Teresa Climent; Blanca Gil-Ibañez Journal: J Pers Med Date: 2022-06-30